Drug price history · CMS NADAC read 11 November 2026

What have pharmacies paid for Cyclophosphamide since 2013?

What pharmacies pay, not what you pay. Cyclophosphamide has 5 products in the CMS NADAC survey, 3 products with year-end prices in more than one year. NADAC is what pharmacies pay to acquire a drug, not what a patient is charged. Cyclophosphamide 50 MG Capsule: $9.34 per unit at the 2014 survey and $1.79 at 2026 (−81%, thin).
Not medical or financial advice. This page reports what pharmacies pay to acquire a drug, from the CMS NADAC survey. It is not what you will be charged, and it says nothing about which medicine is right for you. Ask your pharmacist or prescriber.
Cyclophosphamide5 products in NADAC
3products with a price history
  1. Cyclophosphamide has 5 products in the CMS NADAC survey, 3 products with year-end prices in more than one year. NADAC is what pharmacies pay to acquire a drug, not what a patient is charged.
  2. Between each product's first and latest year-end survey, 1 product costs pharmacies less and none costs more, by more than 5 percent, per unit as CMS states it.
  3. 2 of the changes rest on fewer than 3 priced NDCs at one end and are marked thin: a median over one or two NDCs reflects which NDCs were priced as much as a price movement.
  4. This is a per-unit acquisition cost, not a retail price, a copay or an insurer's price, and it says nothing about why a price moved.

Cyclophosphamide 50 MG Capsule

Generic

$9.34 per unit at the 2014 year-end survey (1 NDC) and $1.79 at the 2026 survey (4 NDCs): −81%, a thin comparison.

$0$11.112014: median $9.34 per unit, 1 NDC priced2015: median $8.76 per unit, 1 NDC priced2016: median $9.40 per unit, 1 NDC priced2017: median $9.58 per unit, 1 NDC priced2019: median $11.11 per unit, 4 NDCs priced2020: median $8.05 per unit, 5 NDCs priced2023: median $4.07 per unit, 4 NDCs priced2024: median $2.73 per unit, 4 NDCs priced2025: median $1.76 per unit, 3 NDCs priced2026: median $1.79 per unit, 4 NDCs priced201420162019202320252026
year-end median across the NDCs pricedlowest to highest NDC
Year-end surveyMedian per unitLowest to highestNDCs priced
2014 (2014-12-31)$9.341
2015 (2015-12-30)$8.761
2016 (2016-12-28)$9.401
2017 (2017-12-27)$9.581
2019 (2019-12-25)$11.114
2020 (2020-12-30)$8.055
2023 (2023-12-27)$4.074
2024 (2024-12-25)$2.734
2025 (2025-12-31)$1.763
2026 (2026-11-11)$1.794

Cyclophosphamide 25 MG Capsule

Generic

$2.41 per unit at the 2024 year-end survey (4 NDCs) and $1.15 at the 2026 survey (4 NDCs): −52%.

$0$2.412024: median $2.41 per unit, 4 NDCs priced2025: median $1.17 per unit, 3 NDCs priced2026: median $1.15 per unit, 4 NDCs priced202420252026
year-end median across the NDCs pricedlowest to highest NDC
Year-end surveyMedian per unitLowest to highestNDCs priced
2024 (2024-12-25)$2.414
2025 (2025-12-31)$1.173
2026 (2026-11-11)$1.154

Cyclophosphamide 50 MG Tablet

Generic

$2.36 per unit at the 2013 year-end survey (1 NDC) and $2.80 at the 2014 survey (1 NDC): +19%, a thin comparison.

$0$2.802013: median $2.36 per unit, 1 NDC priced2014: median $2.80 per unit, 1 NDC priced20132014
year-end median across the NDCs pricedlowest to highest NDC
Year-end surveyMedian per unitLowest to highestNDCs priced
2013 (2013-12-25)$2.361
2014 (2014-12-31)$2.801

Cyclophosphamide 25 MG Tab

Generic

Priced once, at the 2013 year-end survey: $1.32 per unit across 1 NDC.

Year-end surveyMedian per unitLowest to highestNDCs priced
2013 (2013-12-25)$1.321

Cyclophosphamide 500 MG Vial

Generic

Priced once, at the 2013 year-end survey: $228 per unit across 2 NDCs.

Year-end surveyMedian per unitLowest to highestNDCs priced
2013 (2013-12-25)$2282

CMS National Average Drug Acquisition Cost, year-end surveys 2013 to 2026. A pharmacy acquisition cost, not a retail price. About NADAC.

Where does Cyclophosphamide sit on the generic price cliff?

Cyclophosphamide 50 MG Capsule: the first generic approval in its Orange Book group is dated 2018. Its year-end acquisition cost in 2026 is 16% of its first observed year-end price (2019). The median matched product, 8 years after its first generic approval, is at 32% (the middle half runs from 8% to 65%), so this product is inside that middle half.

0%25%50%75%100%0 years after the first generic approval: median 100%, middle half 100% to 100%, 79 products1 years after the first generic approval: median 95%, middle half 71% to 100%, 118 products2 years after the first generic approval: median 80%, middle half 49% to 99%, 135 products3 years after the first generic approval: median 64%, middle half 36% to 90%, 142 products4 years after the first generic approval: median 55%, middle half 25% to 84%, 154 products5 years after the first generic approval: median 46%, middle half 16% to 80%, 154 products6 years after the first generic approval: median 45%, middle half 16% to 87%, 154 products7 years after the first generic approval: median 40%, middle half 14% to 71%, 153 products8 years after the first generic approval: median 32%, middle half 8% to 65%, 131 products9 years after the first generic approval: median 28%, middle half 7% to 67%, 109 products10 years after the first generic approval: median 22%, middle half 5% to 53%, 90 products11 years after the first generic approval: median 21%, middle half 5% to 51%, 79 products12 years after the first generic approval: median 16%, middle half 6% to 34%, 48 products13 years after the first generic approval: median 19%, middle half 14% to 39%, 23 productsCyclophosphamide 50 MG Capsule, 1 years after the first generic approval: 100% of its first observed price, 4 NDCs pricedCyclophosphamide 50 MG Capsule, 2 years after the first generic approval: 72% of its first observed price, 5 NDCs pricedCyclophosphamide 50 MG Capsule, 5 years after the first generic approval: 37% of its first observed price, 4 NDCs pricedCyclophosphamide 50 MG Capsule, 6 years after the first generic approval: 25% of its first observed price, 4 NDCs pricedCyclophosphamide 50 MG Capsule, 7 years after the first generic approval: 16% of its first observed price, 3 NDCs pricedCyclophosphamide 50 MG Capsule, 8 years after the first generic approval: 16% of its first observed price, 4 NDCs priced024681012years since the first generic approval
median of 200 matched productsmiddle halfeach productCyclophosphamide 50 MG Capsule

This is a pattern in matched products. It does not say the first generic caused the fall, and it does not say this product's price will follow the median. See it with other drugs.

How many companies make Cyclophosphamide?

The FDA Orange Book lists 9 generic makers as marketed in its largest dosage form for Cyclophosphamide, and the first generic approval is dated 16 February 1982. The acquisition costs above are what pharmacies pay across the NDCs priced; the Orange Book count is a separate record and this page does not say that more makers lowered a price. See each maker and the patents still listed on OmniRx.

Where can you go from this record?

Open it in the check to search another drug, or see the CMS pharmacy pricing page for what NADAC measures. For who makes the generic and which patents are listed, see the generic competition check for Cyclophosphamide on OmniRx. To check whether a drug is in shortage, see the FDA drug shortages page.

Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the CMS pharmacy pricing page, year-end surveys 2013 to 2026 (latest 11 November 2026).